

CORRECTION

Open Access



# Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8<sup>+</sup> T and NK cells: a novel therapeutic tumour vaccine

Zhaojin Yu<sup>1,2†</sup>, Wensi Liu<sup>1,2†</sup>, Ying He<sup>1,2,4†</sup>, Mingli Sun<sup>1,2</sup>, Jiankun Yu<sup>1,2</sup>, Xue Jiao<sup>1,2</sup>, Qiang Han<sup>1,9</sup>, Haichao Tang<sup>1,2</sup>, Bing Zhang<sup>1,2</sup>, Yunkai Xian<sup>1,2</sup>, Jing Qi<sup>1,2</sup>, Jing Gong<sup>1,2</sup>, Wang Xin<sup>3</sup>, Gang Shi<sup>5</sup>, Fengping Shan<sup>6</sup>, Rui Zhang<sup>5\*</sup>, Jianping Li<sup>1,7,8\*</sup> and Minjie Wei<sup>1,2\*</sup>

## Correction to: *J Hematol Oncol* (2021) 14:71

<https://doi.org/10.1186/s13045-021-01081-7>

The original article [1] contains errors in Figure 3i, Figure 6c and Figure S9:

1. In Fig. 3i, the legends of the line chart were marked incorrectly.
2. In Fig. 6c, the panel of ISA CD8a<sup>+</sup> group was unintentionally duplicated onto the panel of YL-ISA NK1.1<sup>+</sup> group.

3. In Figure S9, the panel of LA-ISA Liver group was misused.

The corrected figures are presented ahead, and the changes do not affect the conclusions of the paper.

The original article can be found online at <https://doi.org/10.1186/s13045-021-01081-7>.

\*Correspondence: zhangrui@cancerhosp-ln-cmu.com; ljp\_63@163.com; mjwei@cmu.edu.cn; weiminjiecmu@163.com

†Zhaojin Yu, Wensi Liu and Ying He have contributed equally to this work


<sup>1</sup> Department of Pharmacology, School of Pharmacy, China Medical University, No. 13, Beihai Road, Dadong District, Shenyang, Liaoning Province, China

<sup>5</sup> Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No.77, Xiaoheyan Road, Dadong District, Shenyang, Liaoning Province, China


Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



**Fig. 3 i** Immunofluorescence analysis of co-localization between LA (green, FITC) and different subcellular compartments (red, early endosome, lysosome or endoplasmic reticulum) in immature DCs (blue, DAPI, nuclear) (n = 3)



**Fig. 6 c** Representative immunohistochemical staining of CD8a and NK1.1 in subcutaneously transplanted tumour tissues

### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13045-021-01176-1>.

**Additional file 1.**

### Author details

<sup>1</sup>Department of Pharmacology, School of Pharmacy, China Medical University, No. 13, Beihai Road, Dadong District, Shenyang, Liaoning Province, China.

<sup>2</sup>Liaoning Key Laboratory of Molecular Targeted Antitumour Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Centre, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumours, Ministry of Education, China Medical University, No.77, Puhe Road, Shenyang North New Area, Shenyang, Liaoning Province, China. <sup>3</sup>Liaoning Medical Diagnosis and Treatment R&D Centre Co. Ltd., Shenyang, Liaoning Province, China. <sup>4</sup>The Third Department of Medical Oncology, The Fourth Hospital of China Medical University, Shenyang City, Liaoning Province, China. <sup>5</sup>Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No.77, Xiaoheyuan Road, Dadong District, Shenyang, Liaoning Province, China. <sup>6</sup>Department of Immunology, College of Basic Medical Science, China Medical University, Shenyang, Liaoning Province, China. <sup>7</sup>Transfusion Medicine Institute, Liaoning Blood Centre, Shenyang, Liaoning Province, China. <sup>8</sup>Transfusion Medicine Institute, Harbin Blood Centre, Harbin, Heilongjiang Province, China. <sup>9</sup>Department of Pharmacy, Harrison International Peace Hospital, Hengshui, Hebei Province, China.

Published online: 29 September 2021

### Reference

1. Yu Z, Liu W, He Y, Sun M, Yu J, Jiao X, Han Q, Tang H, Zhang B, Xian Y, et al. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8(+) T and NK cells: a novel therapeutic tumour vaccine. *J Hematol Oncol*. 2021;14(1):71. <https://doi.org/10.1186/s13045-021-01081-7>.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.